In 2025, Halozyme Therapeutics completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Halozyme Therapeutics has also provided a category-level breakdown for 8 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2025 | 2024 |
|---|---|---|
Total Scope 1 | 1,104.1a | 1,347.71b |
Total Scope 2 | ||
Location-Based | 958.9a | 2,113.45b |
Total Scope 3 | 32,023a | 30.46b |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 0.7906a | 1.3274b |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Halozyme Therapeutics amounted to 2,063 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Halozyme Therapeutics decreased by 40.4%, showing that the company has made progress in taking action to reduce the climate impact of its operations.ab
In 2025, the total Scope 1 emissions of Halozyme Therapeutics were 1,104.1 metric tons of CO₂ equivalent (tCO₂e).a
Compared to the previous year (2024), Halozyme Therapeutics's Scope 1 emissions decreased by 18.08%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.ab
In 2025, Halozyme Therapeutics reported Scope 2 greenhouse gas (GHG) emissions of 958.9 tCO₂e using the location-based method.a
Compared to the previous year (2024), Halozyme Therapeutics's Scope 2 emissions (Location-Based) fell by 54.63% in 2025, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.ab
In 2025, Halozyme Therapeutics reported its Scope 2 emissions using the location-based method.a
In 2025, Halozyme Therapeutics reported 32,023 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2025 disclosure of Halozyme Therapeutics includes a breakdown across 8 of the 15 Scope 3 categories defined by the GHG Protocol, up from 1 in 2024, reflecting improved emissions accounting practices and greater transparency across the company's value chaina
In 2025, Halozyme Therapeutics reported total Scope 3 emissions of 32,023 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.a
Compared to the previous year (2024), Halozyme Therapeutics's Scope 3 emissions increased by 105,031.32%, suggesting that the company faced challenges in reducing emissions across its value chain.ab
In 2025, Halozyme Therapeutics reported emissions for 8 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This partial disclosure allows for some insight into the company's indirect impacts.
In 2025, the largest contributors to Halozyme Therapeutics's Scope 3 emissions were:a
In 2025, Halozyme Therapeutics reported Scope 1 greenhouse gas (GHG) emissions of 1,104.1 tCO₂e and total revenues of USD 1,397 millions. This translates into an emissions intensity of 0.79 tCO₂e per millions USD.a
In 2025, Halozyme Therapeutics reported a Scope 1 emissions intensity of 0.79 tCO₂e per millions USD. Compared to the peer group median of 4.32, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2025, Halozyme Therapeutics ranked 3 out of 21 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Halozyme Therapeutics among the top performers, with one of the lowest emissions intensities relative to peers.a
In 2025, Halozyme Therapeutics reported a total carbon footprint of 34,086 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 876.22% increase compared to 2024, suggesting a rise in emissions across its operations or value chain.ab
The largest contributor to Halozyme Therapeutics's total carbon footprint was Scope 3 emissions, accounting for 93.95% of the company's total carbon footprint, followed by Scope 1 emissions at 3.24%.a